FAM183A: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: FAM183A

NCBI ID: G440585

FAM183A

FAM183A: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Neurodegenerative disorders are a group of progressive diseases that affect the nervous system, leading to a range of symptoms and impairments. These disorders are characterized by the progressive loss of neural cells, leading to the build-up of damaged tissue and the progression of the disease. FAM183A, a protein that has been identified as a potential drug target and biomarker for neurodegenerative disorders, has been the focus of intense research in recent years.

FAM183A: A Protein Linked to Neurodegenerative Disorders

FAM183A is a protein that is expressed in a variety of tissues throughout the body, including the brain. It has been shown to play a role in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and other dementias.

One of the key features of FAM183A is its role in the formation of neurofibrillary tangles, a hallmark of neurodegenerative disorders. Neurofibrillary tangles are composed of abnormal aggregates of the protein tau and beta-amyloid, which are thought to contribute to the progressive neurofibrillary tangles that are observed in neurodegenerative disorders.

FAM183A Interacts with Other Proteins

FAM183A has been shown to interact with a variety of other proteins, including the protein huntingtin. Huntingtin is a protein that has been linked to a variety of neurodegenerative disorders, including Alzheimer's disease. FAM183A has been shown to interact with huntingtin in a variety of ways, including through the formation of aggregates that are similar to those observed in neurodegenerative disorders.

Another protein that has been shown to interact with FAM183A is the protein S100, which is a protein that is expressed in many tissues throughout the body, including the brain. S100 has been shown to interact with FAM183A through the formation of aggregates that are similar to those observed in neurodegenerative disorders.

FAM183A as a Potential Drug Target

The potential drug target for FAM183A is the formation of neurofibrillary tangles and the disruption of normal cellular processes that are associated with neurodegenerative disorders. drugs that are currently being developed to treat neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, target the formation of neurofibrillary tangles and disrupt the disruption of normal cellular processes that are associated with these disorders.

FAM183A as a Biomarker

FAM183A has also been shown to be a potential biomarker for neurodegenerative disorders. The formation of neurofibrillary tangles and the disruption of normal cellular processes that are associated with neurodegenerative disorders are often detected using biomarkers that are derived from neurofibrils, such as FAM183A. These biomarkers can be used to diagnose neurodegenerative disorders and to monitor the effectiveness of treatments.

Conclusion

FAM183A is a protein that has been identified as a potential drug target and biomarker for neurodegenerative disorders. Its role in the formation of neurofibrillary tangles and the disruption of normal cellular processes that are associated with these disorders makes it an attractive target for drug development. Further research is needed to fully understand the role of FAM183A in neurodegenerative disorders and to develop effective treatments.

Protein Name: Family With Sequence Similarity 183 Member A

Functions: Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating

The "FAM183A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM183A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets